Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor

Journal of Neuroinflammation

M Cristina Morganti-Kossmann²  Nicole Bye¹  Dasuni S Alwis³  Edwin B Yan³  Sarah C Hellewell¹ 

[1] Department of Surgery, Monash University, Level 4, Burnet Tower, 89 Commercial Road, Melbourne, VIC 3000, Australia;Barrow Neurological Institute, Department of Child Health, University of Arizona, Level 5, Burnet Tower, 89 Commercial Road, Melbourne, VIC 3000, Australia;Department of Physiology, Monash University, Clayton, VIC 3800, Australia

关键词: Neuroprotection;    EPO;    Erythropoietin;    Hypoxia;    Traumatic axonal injury;    Traumatic brain injury (TBI);   

Others  :  826170
DOI  :  10.1186/1742-2094-10-156

 received in 2013-10-11, accepted in 2013-12-05,  发布年份 2013

【 摘 要 】

Background

Diffuse axonal injury is a common consequence of traumatic brain injury (TBI) and often co-occurs with hypoxia, resulting in poor neurological outcome for which there is no current therapy. Here, we investigate the ability of the multifunctional compound erythropoietin (EPO) to provide neuroprotection when administered to rats after diffuse TBI alone or with post-traumatic hypoxia.

Methods

Sprague–Dawley rats were subjected to diffuse traumatic axonal injury (TAI) followed by 30 minutes of hypoxic (Hx, 12% O₂) or normoxic ventilation, and were administered recombinant human EPO-α (5000 IU/kg) or saline at 1 and 24 hours post-injury. The parameters examined included: 1) behavioural and cognitive deficit using the Rotarod, open field and novel object recognition tests; 2) axonal pathology (NF-200); 3) callosal degradation (hematoxylin and eosin stain); 3) dendritic loss (MAP2); 4) expression and localisation of the EPO receptor (EpoR); 5) activation/infiltration of microglia/macrophages (CD68) and production of IL-1β.

Results

EPO significantly improved sensorimotor and cognitive recovery when administered to TAI rats with hypoxia (TAI + Hx). A single dose of EPO at 1 hour reduced axonal damage in the white matter of TAI + Hx rats at 1 day by 60% compared to vehicle. MAP2 was decreased in the lateral septal nucleus of TAI + Hx rats; however, EPO prevented this loss, and maintained MAP2 density over time. EPO administration elicited an early enhanced expression of EpoR 1 day after TAI + Hx compared with a 7-day peak in vehicle controls. Furthermore, EPO reduced IL-1β to sham levels 2 hours after TAI + Hx, concomitant to a decrease in CD68 positive cells at 7 and 14 days.

Conclusions

When administered EPO, TAI + Hx rats had improved behavioural and cognitive performance, attenuated white matter damage, resolution of neuronal damage spanning from the axon to the dendrite, and suppressed neuroinflammation, alongside enhanced expression of EpoR. These data provide compelling evidence of EPO’s neuroprotective capability. Few benefits were observed when EPO was administered to TAI rats without hypoxia, indicating that EPO’s neuroprotective capacity is bolstered under hypoxic conditions, which may be an important consideration when EPO is employed for neuroprotection in the clinic.

【 授权许可】

   
2013 Hellewell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Gennarelli TA, Thibault LE, Graham DI: Diffuse axonal injury: an important form of traumatic brain damage. Neuroscientist 1998, 4:202-215.
• [2]Miller JD, Sweet RC, Narayan RK, Becker DP: Early insults to the injured brain. JAMA 1978, 240:439-442.
• [3]Chi JH, Knudson MM, Vassar MJ, McCarthy MC, Shapiro MB, Mallet S, Holcroft JJ, Moncrief H, Noble J, Wisner D, Kaups KL, Bennick LD, Manley GT: Prehospital hypoxia affects outcome in patients with traumatic brain injury: a prospective multicenter study. J Trauma 2006, 61:1134-1141.
• [4]Chesnut RM: Secondary brain insults after head injury: clinical perspectives. New Horiz- Sci Pract 1995, 3:366-375.
• [5]Rockswold GL, Quickel RR, Rockswold SB: Hypoxia and traumatic brain injury. J Neurosurg 2006, 104:170-171.
• [6]Jones PA: Measuring the burden of secondary insults in head-injured patients during intensive care. J Neurosurg Anesthesiol 1994, 6:4-14.
• [7]McHugh GS, Engel DC, Butcher I, Steyerberg EW, Lu J, Mushkudiani N, Hernández AV, Marmarou A, Maas AIR, Murray GD: Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007, 24:287-293.
• [8]Hallam TM, Floyd CL, Folkerts MM, Lee LL, Gong Q-Z, Lyeth BG, Muizelaar JP, Berman RF: Comparison of behavioural deficits and acute neuronal degeneration in rat lateral fluid percussion and weight-drop brain injury models. J Neurotrauma 2004, 21:521-539.
• [9]Ishige N, Pitts L, Hashimotos T, Nishimura M, Bartkowski H: The effects of hypoxia on traumatic brain injury in rats: Part 1: alterations in neurologic function, electroencephalograms, and histopathology. Neurosurgery 1987, 20:848-853.
• [10]Yan EB, Hellewell SC, Bellander BM, Agyapomaa DA, Morganti-Kossmann MC: Post-traumatic hypoxia exacerbates neurological deficit, neuroinflammation and cerebral metabolism in rats with diffuse traumatic brain injury. J Neuroinflamm 2011, 8:147. BioMed Central Full Text
• [11]Gabrielian L, Willshire LW, Helps SC, van den Heuvel C, Mathias J, Vink R: Intracranial pressure changes following traumatic brain injury in rats: lack of significant change in the absence of mass lesions or hypoxia. J Neurotrauma 2011, 28:2103-2111.
• [12]Ito J, Marmarou A, Barzo P, Fatouros P, Corwin F: Charaterization of edema by diffusion-weighted imaging in experimental traumatic brain injury. J Neurosurg 1996, 84:97-103.
• [13]Ghabriel M, Zhu C, Imran A, Blumbergs P, Reilly P: Blood–brain barrier ultrastructural changes in impact acceleration head trauma. In 7th International Neurotrauma Symposium. Adelaide, Australia: Medimond; 2004:89-92.
• [14]Gao G, Oda Y, Wei EP, Povlishock JT: The adverse pial arteriolar and axonal consequences of traumatic brain injury complicated by hypoxia and their therapeutic modulation with hypothermia in rat. J Cereb Blood Flow Metab 2010, 30:628-637.
• [15]Hellewell SC, Yan EB, Agyapomaa DA, Bye N, Morganti-Kossmann MC: Post-traumatic hypoxia exacerbates brain tissue damage: analysis of axonal injury and glial responses. J Neurotrauma 2010, 27:1997-2010.
• [16]Maas AIR, Marmarou A, Murray GD, Teasdale GM, Steyerberg EW: Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J Neurotrauma 2007, 24:232-238.
• [17]Smith DH, Hicks R, Povlishock JT: Therapy development for diffuse axonal injury. J Neurotrauma 2013, 30:307-323.
• [18]Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H: Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol 2010, 24:573-594.
• [19]Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999, 19:643-651.
• [20]Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-de Vicente E, Reina M, Vilaro S, Fabre M: Erythropoietin protects the in vitro blood–brain barrier against VEGF-induced permeability. Eur J Neurosci 2003, 18:2538-2544.
• [21]Weber A, Dzietko M, Berns M, Felderhoff-Mueser U, Heinemann U, Maier RF, Obladen M, Ikonomidou C, Buhrer C: Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 2005, 20:594-600.
• [22]Lu D, Mahmood A, Qu C, Goussev A, Schallert T, Chopp M: Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 2005, 22:1011-1017.
• [23]Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG: Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 2007, 1182:99-105.
• [24]Xiong Y, Lu DY, Qu CS, Goussev A, Schallert T, Mahmood A, Chopp M: Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice- laboratory investigation. J Neurosurg 2008, 109:510-521.
• [25]Xiong Y, Mahmood A, Lu D, Qu CS, Kazmi H, Goussev A, Zhang ZG, Noguchi CT, Schallert T, Chopp M: Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Brain Res 2008, 1230:247-257.
• [26]Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X: Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett 2007, 425:177-182.
• [27]Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovich AG, Tsenter J, Shohami E: Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005, 19:1701-1721.
• [28]Lieutaud T, Andrews PJ, Rhodes JK, Williamson R: Characterisation of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1β and MIP-2 in rats. J Neurotrauma 2008, 25:1179-1185.
• [29]Bian X-X, Yuan X-S, Qi C-P: Effect of recombinant human erythropoietin on serum S110B protein and interleukin-6 levels after traumatic brain injury in the rat. Neurol Med Chir 2010, 50:361-366.
• [30]Valable S, Francony G, Bouzat P, Fevre MC, Mahious N, Bouet V, Farion R, Barbier E, Lahrench H, Remy C, Petit E, Segebarth C, Bernaudin M, Payen JF: The impact of erythropoietin on short-term changes in phosphorylation of brain protein kinases in a rat model of traumatic brain injury. J Cereb Blood Flow Metab 2009, 30:361-369.
• [31]Bouzat P, Francony G, Thomas S, Valable S, Mauconduit F, Fevre MC, Barbier EL, Bernaudin M, Lahrech H, Payen JF: Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative. Crit Care Med 2011, 39:2099-2105.
• [32]Verdonck O, Lahrench H, Francony G, Carle O, Farion R, Van de Looij Y, Remy C, Segebarth C, Payen JF: Erythropoietin protects from post-traumatic edema in the rat brain. J Cereb Blood Flow Metab 2007, 27:1369-1376.
• [33]Foda MA, Marmarou A: A new model of diffuse brain injury in rats. Part II: Morphological characterization. J Neurosurg 1994, 80:301-313.
• [34]Minnerup J, Heidrich J, Rogalewski A, Schabitz W-R, Wellmann J: The efficacy of erythropoietin and its analogues in animal stroke models. Stroke 2009, 40:3113-3120.
• [35]Meng YL, Xiong Y, Mahmood A, Zhang YL, Qu C, Chopp M: Dose-dependent neurorestorative effects of delayed treatement of traumatic brain injury with recombinant human erythropoietin in rats. J Neurosurg 2011, 115:550-560.
• [36]Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW: The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994, 11:187-196.
• [37]Ennaceur A, Delacour J: A new one-trial test for neurobiological studies of memory in rats: I. Behavioural data. Behav Brain Res 1988, 31:47-59.
• [38]Winters BD, Saksida LM, Bussey TJ: Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 2008, 32:1055-1070.
• [39]Albasser MM, Chapman RJ, Amin E, Iordanova MD, Vann SD, Aggleton JP: New behavioural protocols to extend our knowledge of rodent object recognition memory. Learn Mem 2010, 17:407-419.
• [40]Gennarelli TA, Thibault LE, Adams JH, Graham DI, Thompson CJ, Marcincin RP: Diffuse axonal injury and traumatic coma in the primate. Ann Neurol 1982, 12:564-574.
• [41]Xiong Y, Mahmood A, Zhang YL, Meng YL, Zhang ZG, Qu C, Sager T, Chopp M: Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury. J Neurosurg 2010, 114:549-559.
• [42]Hino A, Mizukawa N, Tenjin H, Imahori Y, Taketomo S, Yano I, Nakahashi H, Hirakawa K: Postoperative hemodynamic and metabolic changes in patients with subarachnoid hemorrhage. Stroke 1989, 20:1504-1510.
• [43]Kocher M: Metabolic and hemodynamic activation of postischemic rat brain by cortical spreading depression. J Cereb Blood Flow Metab 1990, 10:564-571.
• [44]Springborg JB, Ma XD, Rochat P, Moos Knudsen G, Amtorp O, Paulson OB, Juhler M, Vidiendal Olsen N: A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002, 135:823-829.
• [45]Rex TS, Wong Y, Kodali K, Merry S: Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp Eye Res 2009, 89:735-740.
• [46]Kumral A, Uysal N, Tugyan K, Sonmez A, Yilmaz O, Gokmen N, Kiray M, Genc S, Durman N, Koroglu T, Ozkan H, Genc K: Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behav Brain Res 2004, 153:77-86.
• [47]Spandou E, Papadopoulou Z, Soubasi V, Karkavelas G, Simeonidou C, Pazaiti A, Guiba-Tziampiri O: Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia–ischemia in rats. Brain Res 2005, 1045:22-30.
• [48]Fan X, Heijnen CJ, van der Kooij MA, Groenendaal F, van Bel F: Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice. Pediatr Res 2011, 69:56-61.
• [49]Varma S, Cohen HJ: Co-transactivation of the 3' erythropoietin hypoxia inducible enhancer by the HIF-1 protein. Blood Cells Mol Dis 1997, 23:169-176.
• [50]Maloyan A, Eli-Berchoer L, Semenza GL, Gerstenblith G, Stern MD, Horowitz M: HIF-1α- targeted pathways are activated by heat acclimation and contribute to acclimation-ischemic cross-tolerance in the heart. Physiol Genomics 2005, 23:79-88.
• [51]Fandrey J: Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol-Regul Integr Comp Physiol 2004, 286:R977-R988.
• [52]Bramlett HM, Dietrich WD: Quantitative structural changes in white and gray matter 1 year following traumatic brain injury in rats. Acta Neuropathol 2002, 103:607-614.
• [53]Assaf Y, Holokovsky A, Berman E, Shapira Y, Shohami E, Cohen Y: Diffusion and perfusion magnetic resonance imaging following closed head injury in rats. J Neurotrauma 1999, 16:1165-1176.
• [54]Farkas E, Donka G, de Vos RA, Mihály A, Bari F, Luiten PG: Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol 2004, 108:57-64.
• [55]DeWitt DS, Smith TG, Deyo DJ, Miller KR, Uchida T, Prough DS: L-Arginine and superoxide dismutase prevent or reverse cerebral hypoperfusion after fluid-percussion traumatic brain injury. J Neurotrauma 2009, 14:223-233.
• [56]Terayama Y, Stirling Meyer J, Kawamura J, Weathers S: Cognitive recovery correlates with white-matter restitution after head injury. Surg Neurol 1993, 39:177-186.
• [57]Abdel-Dayem H, Abu-Judeh H, Kumar M, Atay S, Naddaf S, El-Zeftawy H, Luo J-Q: SPECT brain perfusion abnormalities in mild or moderate traumatic brain injury. Clin Nucl Med 1998, 23:309-317.
• [58]Montero M, Poulsen FR, Noraberg J, Kirkeby A, van Beek J, Leist M, Zimmer J: Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp Neurol 2006, 204:106-117.
• [59]Ballough GP, Cann FJ, Graham JS, Smith CD, Kling CE, Forster JS, Phann S, Filbert MG: Microtubule-associated protein 2 (MAP-2): a sensitive marker of seizure-related brain damage. J Neurosci Methods 1995, 61:23-32.
• [60]Posmantur RM, Kampfl A, Taft WC, Bhattacharjee M, Dixon CE, Bao J, Hayes RL: Diminished microtubule-associated protein 2 (MAP2) immunoreactivity following cortical impact brain injury. J Neurotrauma 1996, 13:125-137.
• [61]Taft WC, Yang K, Dixon CE, Hayes RL: Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. J Neurotrauma 1992, 9:281-290.
• [62]Neumann D, Yuk MH, Lodish HF, Lederkremer GZ: Blocking intracellular degradation of the erythropoietin and asialoglycoprotein receptors by calpain inhibitors does not result in the same increase in the levels of their membrane and secreted forms. Biochem J 1996, 15:391-399.
• [63]Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor proporties of erythroid cells. J Biol Chem 1993, 268:11208-11216.
• [64]Juul SE, Anderson DK, Li Y, Christensen RD: Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998, 43:40-49.
• [65]Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M: Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996, 8:666-676.
• [66]Sirén A-L, Knerlich F, Poser W: Erythropoiein and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001, 101:271-276.
• [67]Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, Gassmann M: Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 1995, 92:3717-3720.
• [68]Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, Mackenzie ET, Petit E: Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000, 30:271-278.
• [69]Lewczuk P, Hasselblatt M, Kamrowski-Kruck H, Heyer A, Unzicker C, Sirén AL, Ehrenreich H: Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport 2000, 11:3485-3488.
• [70]Spandou E, Papoutsopoulou S, Soubasi V, Karkavelas G, Simeonidou C, Kremenopoulos G, Guiba-Tziampiri O: Hypoxia–ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain. Brain Res 2004, 1021:167-172.
• [71]Mazur M, Miller RH, Robinson S: Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury Laboratory investigation. J Neurosurg - Pediatr 2010, 6:206-221.
• [72]Keller M, Yang JL, Griesmaier E, Gorna A, Sarkozy G, Urbanek M, Gressens P, Simbruner G: Erythropoietin is neuroprotective against NMDA-receptor-mediated excitotoxic brain injury in newborn mice. Neurobiol Dis 2006, 24:357-366.
• [73]Li Y, Lu ZY, Keogh CL, Yu SP, Wei L: Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2007, 27:1043-1054.
• [74]Liao ZB, Zhi XG, Shi QH, He ZH: Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol 2008, 15:140-149.
• [75]Schober ME, Block B, Beachy JC, Statler KD, Giza CC, Lane RH: Early and Sustained Increase in the Expression of Hippocampal IGF-1, But Not EPO, in a Developmental Rodent Model of Traumatic Brain Injury. J Neurotrauma 2010, 27:2011-2020.
• [76]Xiong Y, Mahmood A, Qu C, Kazmi H, Zhang ZG, Noguchi CT, Schallert T, Chopp M: Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neuronal erythropoietin receptor. J Neurotrauma 2010, 27:205-215.
• [77]Sakanaka M, Wen T-C, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998, 95:4635-4640.
• [78]Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU: Erythropoietin and Erythropoietin Receptors in Human CNS Neurons, Astrocytes, Microglia, and Oligodendrocytes Grown in Culture. J Neuropathol Exp Neurol 2001, 60:386-392.
• [79]Chen ZY, Warin R, Noguchi CT: Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener Dis 2006, 3:68-75.
• [80]Brines M, Cerami A: Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264:405-432.
• [81]Sanchez PE, Fares RP, Risso J-J, Bonnet C, Bouvard S, Le Cavorsin M, Georges B, Moulin C, Belmeguenai A, Bodennec J, Morales A, Pequignot JM, Baulieu EE, Levine RA, Bezin L: Optimal neuroprotection by erythropoietin requires elevation expression of its receptor in neurons. Proc Natl Acad Sci USA 2009, 106:9848-9853.
• [82]Rabie T, Marti HH: Brain protection by erythropoietin: a manifold task. Physiology 2008, 23:263-274.
• [83]Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R: A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994, 269:19488-19493.
• [84]Colin E, Zala D, Lio TG, Rangone H, Borrell-Pages M, Li XJ, Saudou F, Humbert S: Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. Embo J 2008, 27:2124-2134.
• [85]Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, McIntosh T: The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol 2001, 24:169-181.
• [86]Stoll G, Jander S, Schroeter M: Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Volume 513. New York, NY: Kluwer Academic/Plenum Publ; 2002.
• [87]Giulian D, Corpuz M, Chapman S, Mansouri M, Robertson CS: Reactive mononuclear phagocytes release neurotoxins after ischemic and traumatic injury to the central nervous system. J Neurosci Res 1993, 36:681-693.
• [88]Satoh JI, Kuroda Y: Cytokines and neurotrophic factors fail to affect Nogo-A mRNA expression in differentiated human neurones: implications for inflammation-related axonal regeneration in the central nervous system. Neuropathol Appl Neurobiol 2002, 28:95-106.
• [89]Utagawa A, Bramlett HM, Daniels L, Lotocki G, Dekaban GA, Weaver LC, Dietrich WD: Transient blockage of the CD11d/CD18 intergrin reduces contusion volume and macrophage infiltration after traumatic brain injury in rats. Brain Res 2008, 1207:155-163.
• [90]Basu A, Krady JK, O'Malley M, Styren SD, DeKosky ST, Levison SW: The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci 2002, 22:6071-6082.
• [91]Tehranian R, Andell-Jonsson S, Beni SM, Yatsiv I, Shohami E, Bartfai T, Lundkvist J, Iverfeldt K: Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 2002, 19:939-951.